Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy.
HLA class I
T cell receptor
TCR
TCR-T
TIL therapy
TILs
cancer immunotherapy
peptide-HLA
tumor-infiltrating lymphocytes
Journal
Cell
ISSN: 1097-4172
Titre abrégé: Cell
Pays: United States
ID NLM: 0413066
Informations de publication
Date de publication:
03 08 2023
03 08 2023
Historique:
received:
17
07
2022
revised:
20
04
2023
accepted:
24
06
2023
medline:
7
8
2023
pubmed:
26
7
2023
entrez:
25
7
2023
Statut:
ppublish
Résumé
The T cells of the immune system can target tumors and clear solid cancers following tumor-infiltrating lymphocyte (TIL) therapy. We used combinatorial peptide libraries and a proteomic database to reveal the antigen specificities of persistent cancer-specific T cell receptors (TCRs) following successful TIL therapy for stage IV malignant melanoma. Remarkably, individual TCRs could target multiple different tumor types via the HLA A
Identifiants
pubmed: 37490916
pii: S0092-8674(23)00696-7
doi: 10.1016/j.cell.2023.06.020
pii:
doi:
Substances chimiques
Antigens, Neoplasm
0
Epitopes
0
Receptors, Antigen, T-Cell
0
Banques de données
ClinicalTrials.gov
['NCT00937625']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3333-3349.e27Subventions
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/H001085/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 220295/Z/20/Z
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests The authors have patents granted and pending on T cell recognition of cancer via Melan A, BST2, and/or IMP2.